This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 149 entries.
Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has released an analysis outlining the strong market opportunities for our most recent asset acquisition, Sofpironium Bromide. Within the report, analyst Seth Lizee commented: “Sofpironium Bromide’s target patient population is estimated to be ~3.7 million people in the United States, equal to the estimated […]
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company announcement that the FDA filing timeline for Sofpironium Bromide had been accelerated. Click here to view the report.
Botanix has today announced the New Drug Approval (NDA) submission to the FDA for our recently acquired dermatology asset, Sofpironium Bromide for the treatment of excessive underarm sweating, will now be ready to file in Q3 2022. The Company also provided an update on its pipeline clinical studies. Both the rosacea (BTX1702) Phase 1/2 clinical […]
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the acquisition of our dermatology asset Sofpironium Bromide. Click here to view the report.
🗞 MAKING HEADLINES Herald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide. This novel potential treatment for primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweat, is bringing new hope for sufferers. […]
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the Company’s recent acquisition of Sofpironium Bromide. The deal has been called a “transformational acquisition”. Click here to view the report.
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the acquisition of our dermatology asset Sofpironium Bromide. Click here to view the report.
Botanix Pharmaceuticals (ASX: BOT) hosted an investor update webinar following the announcement of its acquisition of Sofpironium Bromide, the first and only novel treatment for primary axillary hyperhidrosis. Present on the call was President and Executive Chairman, Vince Ippolito; Executive Director, Matt Callahan; Chief Medical Adviser, Dr Patricia Walker; and Chief Commercial Officer, Howie McKibbon.
Botanix President and Executive Chairman, Vince Ippolito, is a world-leading dermatology executive. In this video, he explains why today’s announcement of our acquisition of Sofpironium Bromide is such a promising commercial opportunity for Botanix – as the first and only new chemical entity developed for the treatment of primary axillary hyperhidrosis.
Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince Ippolito joins Kerry Stevenson on Small Caps to discuss the company’s acquisition of novel dermatology asset Sofpironium Bromide gel.
